Abstract: We investigated the relationship between ‘epigenetic age’ (EA) derived from DNA methylation (DNAm) and myocardial infarction (MI)/acute coronary syndrome (ACS). A random population sample was examined in 2003/2005 (n = 9360, 45–69, the HAPIEE project) and followed up for 15 years. From this cohort, incident MI/ACS (cases, n = 129) and age- and sex-stratified controls (n = 177) were selected for a nested case-control study. Baseline EA (Horvath’s, Hannum’s, PhenoAge, Skin and Blood) and the differences between EA and chronological age (CA) were calculated (ΔAH, ΔAP, ΔAASB). EAs by Horvath’s, Hannum’s and Skin and Blood were close to CA (median absolute difference, MAD, of 1.08, –1.91 and –2.03 years); PhenoAge had MAD of −9.29 years vs. CA. The adjusted odds ratios (ORs) of MI/ACS per 1–year increments of ΔAH, ΔAP, ΔAASB and ΔAPh were 1.01 (95% CI 0.95–1.07), 1.01 (95% CI 0.95–1.08), 1.02 (95% CI 0.97–1.06) and 1.01 (0.93–1.09), respectively. When classified into tertiles, only the highest tertile of ΔAPh showed a suggestion of increased risk of MI/ACS with OR 2.09 (1.13–3.94) independent of age and 1.84 (0.99–3.52) in the age- and sex-adjusted model. Metabolic modulation may be the likely mechanism of this association. In conclusion, this case-control study nested in a prospective population-based cohort did not find strong associations between accelerated epigenetic age markers and risk of MI/ACS. Larger cohort studies are needed to re-examine this important research question.

Keywords: DNA methylation; epigenetic age; myocardial infarction; acute coronary syndrome; population; nested case-control; HAPIEE project

1. Introduction

Increasing life expectancy worldwide is accompanied by an aging population. Currently, there are at least 900 million people over 60 years old in the world and, according to the United Nations estimates, the world’s population is expected to reach 8.6 billion people by 2030, of which more than 1.4 billion will be over the age of 60 [1].

Cardiovascular diseases (CVDs), particularly atherosclerotic CVDs such as coronary heart disease (CHD) and cerebrovascular diseases, are the leading cause of mortality and morbidity, being responsible for about 30% of global deaths [2], and aging is a major risk factor. In the multidimensional process of decline in health status during aging, molecular markers of ‘biological age’ are regarded as determinants of the rate of aging.
Epigenetic modifications such as DNA methylation (DNAm) have been shown to be the most accurate molecular readout of aging but their possible functional role remains poorly understood [3,4]. Altered epigenetic patterns may therefore be important causes and/or signals of this aging process.

Epigenetic modifications are mitotically (and in some cases meiotically) heritable. They can change gene and genome function independently of changes in the nucleotide sequence of the DNA [5]. The epigenetic phenomenon of DNAm involves the addition or removal of a methyl group to the 5’ cytosines, most commonly in the context of CpG dinucleotides; areas of relatively high CpG density are referred to as CpG islands which are often associated with a gene promoter [6]. DNAm can be measured quantitatively, and it is increasingly used in human studies [7].

It has been repeatedly shown that DNAm levels at specific sites in the genome are strongly associated with age and that, in some cases, it has been used to accurately predict chronological age [6,8–10]. These sites underline the concept of ‘epigenetic clocks’ and several DNAm-based estimators of chronological age, referred to as ‘epigenetic age’, have been constructed [11]. Hannum’s Blood-based clock is based on 71 CpG sites [9], Horvath’s Pan-Tissue clock is based on 353 CpG sites [12], Levine’s PhenoAge clock is based on 513 CpG sites capturing age-related and functional phenotype modifications [13] and Horvath’s Skin and Blood clock is based on 391 CpGs for human fibroblasts and other cell types [14]. Further to these, over 30 epigenetic clocks have been published [15], including those recently developed on the base of the Illumina Methylation EPIC 850 BeadChip (850 K) [16].

In our study, we chose to use Horvath’s and Hannum’s clocks because they are among the most popular first-generation clocks and are featured (and continue to be used) in many studies of associations between age and phenotypes. The Skin and Blood clock was chosen as an example of a specialized second-generation clock which is known in the research community as the most accurate chronological age predictor reported to date. PhenoAge, which is another second-generation clock, was also chosen based on its popularity among age–trait association studies, including mortality.

We would like to note that second-generation clocks (PhenoAge, GrimAge [17], etc.) are less precise in terms of chronological age prediction in comparison to first-generation or specialized epigenetic clocks. This is because those clocks were designed to incorporate other phenotypes (or comorbidities) and were not primarily aimed at reflecting chronological age. In our experience, PhenoAge is usually well below the chronological age in the vast majority of moderately healthy individuals, which is supported by several publications, including [13,18].

A number of studies have shown an association between epigenetic age and risk of mortality, as summarized in various meta-analyses [19–24]. Both positive and negative correlations have been made on the relationship between epigenetic age and CVD and, specifically, CHD [15,21,24,25], however, these studies are limited, heterogeneous in design and the findings remain largely inconclusive.

In Russia, the proportion of the elderly population is growing, but life expectancy at birth remains on average 8 years lower than in Western Europe [26,27], although the causes of this gap remain unclear [28–30]. This points toward the need to understand all aspects of aging in the Russian population. There have been no longitudinal studies of the relationship between epigenetic measures of age and CVD and chronic diseases in the Russian population. For these reasons, the current analysis is relevant both locally and across the world at large.

Objective of our study was to investigate the relationship between epigenetic age (EA) and myocardial infarction (MI)/acute coronary syndrome (ACS) in a population-based nested case-control study.
2. Methods

2.1. Study Population and Design

A random population sample was examined in the Russian arm of the HAPIEE study at baseline in 2003/05 (n = 9360, age 45–69) and re-examined in 2006–2008 and 2015–2017. The cohort was followed up until 31.12.2019 for an average of 15.9 (SD 0.64, median 15.9) years for fatal and non-fatal cardiovascular events and all-cause mortality.

Data on fatal and non-fatal coronary heart disease (CHD) (ICD–10: I20–I25) events were collected at the Research Institute of Internal and Preventive Medicine (IIPM) using a Register of Myocardial Infarction originally established in the WHO MONICA project by combining ‘hot pursuit’ and ‘cold pursuit’ methods and using medical records and hospital discharge reports. The data on all-cause and cause-specific mortality were collected at the IIPM using various sources, including the Population Registration Bureau (ZAGS) and the Novosibirsk Office of the State Statistical Bureau (Rosstat), and information received at repeated waves of the study (this includes the address bureau, as well as contacts with relatives of deceased study participants).

2.2. Sample Selection Process

During a 15-year follow-up period, 1475 events of myocardial infarction (MI) or acute coronary syndrome (ACS) were ascertained in 9360 unique persons including serial events in some individuals. Using a nested case-control study design, we applied the following exclusion criteria for selecting MI/ACS cases in this study: prevalent baseline CVD (MI, ACS, stroke), data not available for DNA analysis. Exclusion criteria for selection in the control group of this study were the same, with additional exclusion of controls with baseline cancer or those who died before the end of follow-up. We then randomly selected participants with incident MI/ACS (cases) and age- and sex-frequency matched controls. Assuming that a small proportion of DNA samples would be unavailable or rejected by quality control, we selected initially 161 cases and 243 controls. Among them, 139 cases and 187 controls were available and appropriate for DNAm profiling. After DNAm quality control (procedures are described below), 129 cases and 177 controls were included in the analysis. DNAm profiles of 88 subjects available from the earlier pilot study [31] were included in the sampling algorithm and were included in the ‘expanded control group’ (n = 265) for additional analyses. The general characteristics of expanded controls are summarized in Table S2.

2.3. Ethics

All study participants provided informed consent and study protocols were approved by the ethical committee of the Research Institute of Internal and Preventive Medicine. The study was conducted in accordance with the relevant ethical guidelines and regulations.

2.4. Data Collection

Baseline data collection in the HAPIEE study was conducted using a comprehensive questionnaire, medical examination and the collection of venous blood samples. The protocol included assessment of history of cardiovascular and other chronic diseases, lifestyle habits and health, socio-economic circumstances, objective measurement of blood pressure (BP), anthropometric parameters and physical performance. The details of the protocol are reported elsewhere [32].

The lifestyle habits, health and socio-economic circumstances were assessed by structured interview. A person who smoked at least one cigarette a day was classified as a smoker. Smoking status was categorized as current smoker, former smoker and never smoked.

The level of education was categorized into 4 categories (high, secondary, vocational and primary or less than primary education). For the current analysis, marital status was dichotomized as married (or cohabiting) and single (never been married, divorced or widower/widow).
The height and weight were measured with accuracy to 1 mm and 100 g, respectively; body mass index (BMI) was calculated as kg/m$^2$. Blood pressure (BP) was measured three times (Omron M-5 tonometer) on the right arm in a sitting position after a 5 min rest period with a 2 min interval between measurements. The average of three BP measurements was calculated.

Blood samples were drawn following at least 8 h of fasting. Serum was stored at minus 80 °C and analyses for lipids and glucose were conducted within one month after sample collection. The levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDLC) and glucose in blood serum were measured enzymatically by a KoneLab Prime 30i autoanalyzer (Thermo Fisher Scientific Inc., Waltham, MA, USA) using kits from Thermo Fisher Scientific (Thermo Fisher Scientific Inc., Waltham, MA, USA). Low-density lipoprotein cholesterol (LDLC) was calculated using the Friedewald formula.

Genomic DNA was isolated from whole blood cells by phenol-chloroform extraction and stored at minus 70 °C until further laboratory analysis.

2.5. DNAm Profiling

Whole blood DNAm profiling was performed using Illumina Infinium Methylation EPIC BeadChip arrays following the manufacturer’s recommended protocol (Illumina Inc, San Diego, CA, USA). The arrays were scanned using the iScan Microarray Scanner with an autoloader (Illumina Inc, San Diego, CA, USA) to produce the raw signal intensity files (.idat files) in accordance with standard operating procedures.

2.6. Data Preprocessing and Quality Control (QC)

All the data preprocessing and QC procedures were performed using R version 4.1.0 (R Foundation for Statistical Computing, Vienna, Austria) and dedicated R libraries minfi [33], ChAMP [34] and ENmix [35], following the steps described in [36]. In particular, our QC checks included array control probes’ metrics as described in Illumina Bead Control Reporter guidelines, detection $p$-values and bead count numbers. In addition, we inspected the concordance of the reported sex with one inferred from DNAm data, and for the samples with available repeated DNAm profiling at a different time point, we performed sample matching using the data from 59 EPIC array SNP control probes. In our analysis, we only used data from the samples with less than 1% CpGs with detection $p$-values above the threshold 0.01, and probes (CpGs) with bead count numbers of at least 3 and $p$-values below 0.01 across at least 99% of samples.

2.7. DNAm Age Calculation

Baseline EA was calculated using Horvath’s [12], Hannum’s [9], PhenoAge [13] and Skin and Blood DNAm clocks [14]. The missing probes required for the DNAm age calculation were imputed using the kNN method [37,38], implemented in the ENmix R library. Following the definition in [12], we calculated age acceleration as a difference between EA and chronological age (CA) for each clock. Corresponding age accelerations for Horvath’s, Hannum’s, PhenoAge and Skin and Blood clocks were denoted as $\Delta AHr$, $\Delta AHn$, $\Delta APh$ and $\Delta ASB$, respectively.

2.8. Statistical Analysis

Statistical analysis was conducted using SPSS (v19.0, Inc., Chicago, IL, USA) and R (v4.1.0) software packages (R Foundation for Statistical Computing, Vienna, Austria). The dataset includes 129 MI/ACS cases and 177 controls.

First, descriptive analysis compared chronological age (CA), EA and general characteristics of case and control groups using ANOVA and cross-tabulation techniques.

Second, logistic regression was used to estimate odds ratios of MI/ACS per 1-year increment of EA as a continuous variable. The dependent variable was cases of incident MI/ACS. Model 1 was adjusted for baseline age; Model 2 was adjusted for age and sex; Model 3a was adjusted for age, sex and smoking; Model 4 was adjusted for age, sex,
smoking, systolic blood pressure (SBP), total cholesterol (TC), body mass index (BMI) and education level.

Finally, we classified subjects into tertiles of the difference between EA and CA for the four EA measures ($\Delta$AHr, $\Delta$AHn, $\Delta$APh, $\Delta$ASB), and logistic regression was used to estimate odds ratios of MI/ACS by EA tertile using cases of incident MI/ACS as the dependent variable. For the independent variable (difference between EA and CA), the reference category consisted of the tertile of participants with the smallest EA–CA difference. The tertile cutpoints were $\Delta$AHr (−1.38; 3.26), $\Delta$AHn (−3.95; 0.13), $\Delta$APh (−11.50; −6.21), $\Delta$ASB (−3.52; −0.31). Age-adjusted and multivariable-adjusted models were estimated with the same covariates as above.

3. Results

3.1. Cases and Controls Have Significant Differences in Basic Phenotype Characteristics

After the quality control procedures, the analytical sample consisted of 129 cases and 177 controls. The general characteristics of case and control participants are summarized in Table 1.

Table 1. Distribution of baseline covariates among cases of incident MI/ACS and control (the Russian arm of the HAPIEE study).

| Covariates                        | Cases (Incident MI/ACS) | Controls | $p$-Value $^a$ |
|-----------------------------------|-------------------------|----------|----------------|
| Observed                          | 129                     | 177      |                |
| Age at baseline, years (mean, SD) | 59.8 (6.87)             | 54.5 (6.45) | <0.001         |
| Females (%)                       | 62 (48.1)               | 73 (58.8) | 0.064          |
| Systolic blood pressure, mmHg (mean, SD) | 151.6 (26.93)       | 133.2 (21.87) | <0.001         |
| Diastolic blood pressure, mmHg (mean, SD) | 92.3 (14.36)       | 86.0 (12.69) | <0.001         |
| Body mass index, kg/sqm (mean, SD) | 28.8 (5.73)            | 27.5 (4.90) | 0.031          |
| Total cholesterol mmol/L (mean, SD) | 6.61 (1.27)           | 6.42 (1.28) | 0.204          |
| LDL cholesterol, mmol/L (mean, SD) | 4.32 (1.14)           | 4.15 (1.13) | 0.207          |
| Glucose, plasma, mmol/L (mean, SD) | 6.41 (2.29)           | 5.77 (0.85) | 0.001          |
| Hypertension (%)                  | 96 (74.4)              | 80 (45.2)  | <0.001         |
| Diabetes mellitus type 2 (%)      | 24 (18.9)              | 10 (5.8)   | <0.001         |
| DM2 treatment (among DM2), (%)    | 8 (33.3)               | 3 (30.0)   | 0.850          |
| Frequency of drinking (%)         |                        |           |                |
| Non-drinkers                      | 24 (18.6)              | 15 (8.5)   |                |
| <1/month                          | 55 (42.6)              | 76 (42.9)  |                |
| 1–3/month                         | 25 (19.4)              | 35 (19.8)  | 0.050          |
| 1–4/week                          | 22 (17.1)              | 48 (27.1)  |                |
| 5+/week                           | 3 (2.3)                | 3 (1.7)    |                |
| Smoking (%)                       | 75 (58.1)              | 105 (59.3) |                |
| Never smoked                      |                        |           |                |
| Former smoking                    | 10 (7.8)               | 27 (15.3)  | 0.066          |
| Present smoker                    | 44 (34.1)              | 56 (31.6)  |                |
| Married (%)                       | 96 (74.4)              | 135 (76.3) | 0.405          |
| University education (%)          | 27 (20.9)              | 56 (31.6)  | <0.001         |
| Difference EA–chronological age   |                        |           |                |
| by four measures:                 |                        |           |                |
| $\Delta$AHr, year                 | 0.055 (5.35)           | 1.663 (5.09) | 0.008          |
| $\Delta$AHn, year                 | −2.702 (5.36)          | −1.161 (4.82) | 0.009          |
| $\Delta$APh, year                 | −8.945 (6.43)          | −8.762 (6.38) | 0.806          |
| $\Delta$ASB, year                 | −2.551 (4.06)          | −1.550 (3.58) | 0.023          |

SD—standard deviation; EA—epigenetic age; CVD—cardiovascular disease. $^a$—ANOVA or chi-square test.

The individuals with incident cases of MI/ACS were slightly older, as expected, they had higher BP, anthropometric measures (body mass index, BMI, and waist/hip ratio, WHR) and levels of plasma glucose, more frequently had hypertension (HT) and type 2 diabetes (DM2) and were less educated compared to controls.

DNAm ages calculated by Horvath’s, Hannum’s and Skin and Blood clocks were similar to participants’ CA; the corresponding median absolute differences (MADs) were 1.08, −1.91 and −2.03 years (Figure 1). Means (SD) were 0.98 (5.25), −1.81 (5.10) and −1.97
(3.81) for $\Delta A_{HR}$, $\Delta A_{HN}$ and $\Delta A_{SB}$, respectively. As expected, PhenoAge’s predictions were less precise with $\text{MAD} = -9.29$ and $\Delta A_{Ph}$ mean (SD) $-8.84$ (6.39). Scatterplots of chronological vs. epigenetic age by Horvath’s, Hannum’s, PhenoAge and Skin and Blood clocks are presented in Figure 2 and Figure S1 (Supplementary Material). The correlation coefficients between CA and EA were between 0.688, $p < 0.001$ (for PhenoAge) and 0.856, $p < 0.001$ (for Skin and Blood age), Figure S2 (Supplementary Material). Sex-specific distribution of the epigenetic age acceleration for all four clocks is shown on Supplementary Figure S3.

3.2. Association between Age Acceleration and Risk of MI/ACS

Odds ratios of MI/ACS per 1–year increment of EA measures, modeled as a continuous variable, are presented in Table 2. ORs of MI/ACS per 1–year increment of EA measures were 1.016 (95% CI 0.96–1.07) for $\Delta A_{HR}$; 1.023 (95% CI 0.95–1.08) for $\Delta A_{HN}$; 1.032 (95% CI 0.99–1.07) for $\Delta A_{Ph}$; and 1.002 (95% CI 0.94–1.07) for $\Delta A_{SB}$ in age-adjusted models (Table 2). In multivariable analyses (fully adjusted Model 4), the ORs were 1.009 (95% CI 0.95–1.07), 1.012 (95% CI 0.95–1.08), 1.017 (95% CI 0.97–1.06) and 1.009 (95% CI 0.93–1.09), respectively, and were not statistically significant.
Figure 2. Scatterplots of chronological vs. epigenetic age by Horvath’s, Hannum’s, PhenoAge and Skin and Blood clocks. Diagonal green line corresponds to the predicted age equal to the chronological age, blue straight line corresponds to the linear regression.

Table 2. Relationship between MI/ACS and epigenetic age acceleration, per 1–year increment of the difference between baseline EA and CA (cases, \(n = 129\) and controls, \(n = 177\)).

| Measure of Epigenetic Age | \(n, \text{Case/Control}\) | Model 1 | Model 2 | Model 3 | Model 4 |
|---------------------------|-----------------------------|---------|---------|---------|---------|
| \(\Delta A_{HR}\), per 1 year | 129/177 | 1.016 (0.96–1.07) | 1.003 (0.87–1.36) | 1.008 (0.95–1.06) | 1.009 (0.95–1.07) |
| \(p\)-value for trends | | 0.563 | 0.911 | 0.785 | 0.763 |
| \(\Delta A_{HN}\), per 1 year | 129/177 | 1.023 (0.95–1.08) | 1.001 (0.95–1.06) | 1.006 (0.95–1.07) | 1.012 (0.95–1.08) |
| \(p\)-value for trends | | 0.418 | 0.961 | 0.842 | 0.708 |
| \(\Delta A_{Ph}\), per 1 year | 129/177 | 1.032 (0.99–1.07) | 1.021 (0.98–1.06) | 1.017 (0.98–1.06) | 1.017 (0.97–1.06) |
| \(p\)-value for trends | | 0.126 | 0.310 | 0.430 | 0.459 |
| \(\Delta A_{SB}\), per 1 year | 129/177 | 1.002 (0.94–1.07) | 0.991 (0.93–1.06) | 0.997 (0.93–1.07) | 1.009 (0.93–1.09) |
| \(p\)-value for trends | | 0.962 | 0.802 | 0.927 | 0.825 |

\(\Delta A_{HR}\)—difference between EA by Horvath’s and chronological age; \(\Delta A_{HN}\)—difference between EA by Hannum’s and chronological age; \(\Delta A_{Ph}\)—difference between phenotypic EA and chronological age; \(\Delta A_{SB}\)—difference between Skin and Blood EA and chronological age; OR—odds ratio; CI—confidence interval; Model 1: age-adjusted; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex and smoking; Model 4: adjusted for age, sex, smoking, SBP, TC, BMI and education.

The results are presented separately for men and women in Table S1 and Figure S4 (Supplementary materials). The relationships between EAA and MI/ACS were of the same directions compared to pooled results and were not statistically significant.

Odds ratios of MI/ACS by tertiles of EA measures are presented in Table 3. After controlling for age, the risk of MI/ACS was modestly higher in \(\Delta A_{HR}\) tertile 3 vs. tertile 1: OR = 1.26 (95% CI 0.65–2.44). Similarly, the risk of MI/ACS was higher in tertile 3 of \(\Delta A_{HN}\) compared with the lowest tertile, the OR was 1.57 (95% CI 0.79–3.14). In
multivariable models adjusted for age, sex, smoking, SBP, BMI, total cholesterol and education, the ORs were 1.24 (95% CI 0.60–2.56) and 1.36 (95% CI 0.63–2.96), respectively. However, as the lower margin of 95% confidence intervals was always less than 1.00, it is possible that these results arose by chance alone.

Table 3. Relationship between MI/ACS and epigenetic age acceleration by tertiles of the difference between baseline EA and CA (cases, \( n = 129 \) and controls, \( n = 177 \)).

| Measure of Epigenetic Age | \( n \), Case/Control | Tertiles | Absolute Difference \( T1-T2 \) | \( p \)-value for trends |
|---------------------------|------------------------|---------|-------------------------------|------------------------|
| \( \Delta A H_r \), year    | 129/177                | T1 (ref) | 1.0                           | 1.0                    |
|                           |                        | T2      | 1.02 (0.65–1.63)              | 1.0                    |
|                           |                        | T3      | 1.14 (0.59–2.22)              | 1.0                    |
|                           |                        | T4      | 1.21 (0.61–2.40)              | 1.0                    |
|                           |                        | T5      | 1.24 (0.60–2.56)              | 1.0                    |
| \( p \)-value for trends  |                        |         |                               |                        |

4. Discussion

In this nested case-control study in Novosibirsk (Russia), we selected CVD-free participants with incident MI/ACS (cases) and age- and sex-frequency matched controls from a population-based cohort (HAPIEE); participants were followed up over 15 years. Epigenetic ages derived from DNAm with Horvath’s, Hannum’s and Skin and Blood clocks were close to the chronological ages, but PhenoAge’s predictions were less close to CA. From the EA indices tested in this study, the relationship between incident MI/ACS and 1–year increments of the difference between baseline EA and CA assessed by the PhenoAge clock was positive but statistically not significant. The relationships between the risk of MI/ACS
and acceleration of EA assessed by $\Delta A_Hr$, $\Delta A_Hn$ and $\Delta A_{SB}$ were of the same direction but were weaker and also statistically not significant.

When EAA was classified into tertiles, the risk of MI/ACS modestly increased in tertile 3 vs. tertile 1 of EAA assessed by the PhenoAge clock only in the minimally adjusted model independent of age and was borderline in the age- and sex-adjusted model. This association appeared to be explained (or mediated) by smoking and metabolic factors. We did not find significant associations between EAA tertiles of other studied DNAm clocks and MI/ACS in our sample.

Age is one of the strongest risk factors for many human diseases, including CVD and, specifically, CHD [16,24]. Given the significance of biological aging, a variety of estimators of biological age were constructed. DNAm-based estimators (epigenetic age) precisely predict chronological age and their positive deviation from chronological age is considered as ‘accelerated biological aging’ (EAA).

In our dataset, EAA was higher in the control group than in MI/ACS cases. That could be explained by the differences in chronological ages in case and control group subjects. Indeed, it is known that EAA is non-linear and tends to decrease with age [10], and in our sample, the chronological age at the time of blood draw in the control subjects is lower than that of the cases. To address the potential interaction between chronological age at baseline and EAA, an analysis stratified by age group would be needed; unfortunately, our study was not large enough to do so.

Evidence is growing on the association between epigenetic age and risk of all-cause mortality and some cause-specific mortality [13,19–24]. In a recent meta-analysis, Fransquet et al. (2019) (41,607 subjects) defined that each 5–year increase in epigenetic age acceleration (EAA) was associated with 8% and 15% increased risk of all-cause mortality (by Hannum’s and Horvath’s, correspondingly) [24]. Another meta-analysis of Marioni et al. (2015) [22], based on four large cohorts (two Lothian Birth Cohorts, Framingham Heart Study and Normative Aging Study), revealed a pooled effect of 16% and 9% increases in total mortality risk by 5–year higher EAA (by Hannum’s and Horvath’s, respectively).

EAA has been extensively investigated in relation to age-dependent diseases, health, lifestyle and environmental factors, with inconsistent results [15,21,25,39–42]. In our study, the relationship between MI/ACS and PhenoAge acceleration by 1–year was positive but statistically not significant. We found modestly increased risk of incident MI/ACS in the top vs. the lowest tertile of baseline difference between EA and CA confined to the PhenoAge clock in the minimally adjusted model. The direction of association for PhenoAge is broadly in line with associations between EA acceleration and MI or CHD risk reported in a meta-analysis of five cohorts [13], in the NAS and KORA F4 cohorts [43] and in comparative analysis between GrimAge and other EA estimators [17]. For instance, in the meta-analysis of the NAS cohort ($n = 737$ white men) and KORA F4 cohort ($n = 1725$) with follow-up ranging from 8.5–14 years, the HR of MI was 1.15 per 1 SD of PhenoAge acceleration [43]. In a meta-analysis of five cohorts (WHI (two cohorts), FHS, NAS, JHS), a 1–year increase in PhenoAge was associated with CHD risk with $\beta = 0.016$ to 0.073 [13]. A recent systematic review based on 156 publications and a meta-analysis of 57 factors by Oblack et al. [15] obtained similar effects, with HR for CVD risk ranging from 1.011 to 1.083 per year assessed by four epigenetic clocks (Horvath’s, Hannum’s, PhenoAge and GrimAge).

We observed ORs of MI/ACS ranging from 1.009–1.012 per 1 year of EAA and from 1.2–1.3 in the top tertile vs. the lowest tertile of EAA by Horvath’s and Hannum’s clocks; these coefficients were not statistically significant but close to those previously reported in the ARIC study [44], a German ESTHER case cohort [20] and cumulative data from a recent meta-analysis [15]. For example, in the ARIC study of a sub-cohort of black participants ($n = 2543$) followed for 21 years, the HR of fatal CHD was 1.17 and 1.22 per 5–year increment of Hannum’s and Horvath’s EAA independent of other factors; the HR for MI modestly increased by 1.12 for Hannum’s EAA [44]. In the ESTHER case cohort study ($n = 1864$), the HR of CVD mortality was 1.19 for a 5–year increment of Horvath’s
EAA independent of other factors and similar but weaker for Hannum’s EAA measure [20]. On the other hand, for example, Horvath et al. (2016) [25] did not report an association between EAA and incident CHD in the Women’s Health Initiative dataset.

The OR in our analysis for EAA by PhenoAge tertile was substantially attenuated after controlling for metabolic factors (BMI, SBP, TC) and education. The residual associations, although still of meaningful magnitude, had wide confidence intervals, and they may have arisen by chance alone on account of our relatively small sample size. This is in contrast to some of the larger aforementioned studies that have reported associations in multivariable-adjusted models.

The impact of metabolic risk factors to mediate the relationship between epigenetic age and risk of atherosclerotic CVD and acute coronary outcomes is well supported. Original studies and comprehensive reviews consistently demonstrate that BMI is strongly correlated with epigenetic age, independent of other covariates [15,21,39,45]. Obesity is a known risk factor for many age-related diseases; it is associated with oxidative stress and a pro-inflammatory state that enhances white blood cell turnover and is considered as pro-aging [39]. The exact mechanisms linking DNA methylation profiles and CVD are not entirely clear, but DNAm is considered as a key player in the genetic regulation of genes related to cardiac homeostasis [46]. In the last decade, several DNAm studies (including EWASs) have linked CHD and atherosclerosis to differentially methylated sites related to genes most commonly involved to the pathways of obesity, adiposity, lipid and carbohydrate metabolism, inflammation, macrophage activity, smooth muscle cell proliferation and renin–angiotensin regulation [45,47–51].

The diversity across previous studies in the relationship between EA and CVD/CHD regarding the presence and magnitude of association might be related to the heterogeneity of the studied outcomes and study design, age, ethnic and sex composition and volume of the sample, population-specific characteristics of morbidity, risk factor profiles and environmental exposure, covariates and multiple statistical testing, as well as the exact DNAm platform and EA clocks used in the analysis.

5. Study Limitations and Advantages

The study has several limitations, particularly the relatively small sample size. In this nested case-control study, we randomly selected cases of incident fatal and non-fatal MI and ACS among all new-onset CHD events occurring in a large population cohort (9360) during a 15-year follow-up; the cases and controls were frequency matched by age and sex. This makes it more likely that we obtained a representative sample of typical acute coronary disease for this population, but the study was under-powered to study relatively small effects. The sample size was determined by the numbers of eligible events with DNA samples and by the cost of the lab analyses. In post hoc power calculations (with 160 cases and 240 controls), the estimated statistical power of the analysis to detect a difference between cases and controls in delta (epigenetic age–chronological age) of 1.5 and 2 years was 80% > 90%, respectively. For internal validation, we repeated the analysis using another (expanded) control group which did not significantly alter the results. However, further enlarging of the MI/ACS sample would certainly improve the statistical power to detect significant associations for EAA metrics.

For practical reasons, we used frequency matching of cases and controls by 5–year age groups and sex instead of an individual matching procedure. After exclusions by quality control, the distribution of age groups between cases and controls slightly changed but the statistical adjustment would take this into account. Sex distribution remained practically uniform (50–60%) between cases and controls. We also conducted internal validation using an expanded control sample with age–sex distribution closer to cases (mean age 59.8 years in cases vs. 57.5 years in expanded controls); the use of an expanded sample did not significantly alter the results.

To protect against misclassification which could not be excluded for CHD as a potentially heterogenous outcome, we focused on the most strictly defined categories of
CHD (MI and ACS) ascertained from the data of ‘MI Register’ using standardized and internationally validated criteria. To ensure completeness of registration, we additionally used overlapping sources of case ascertainment and both hot-pursuit and cold-pursuit approaches were combined by MI Register.

Another potential limitation relates to the arguable differences in DNAm between sexes [50]. To overcome this limitation, the sampling procedure kept the sex distribution uniform among cases and controls (nearly 50–60%), and we adjusted the estimates by sex (Model 2). Finally, in the sensitivity analysis split by sex we received ORs of the same directions and similar values compared to pooled results and they were insignificant (data are shown in Supplement Material, Table S1).

Our study also has several strengths. First, it is the first population-based prospective nested case-control study exploring the relationship between epigenetic age and risk of incident MI/ACS in the Russian population as well as in the Eastern European population.

Second, we used the latest platform, Illumina Epic 850 BeadChip, for DNA methylation analysis, applied standardized multistep quality control and included longitudinal analysis at a different time point. We only used high-quality data from samples with less than 1% CpGs with detection p-values above the threshold 0.01, and CpGs with bead count numbers of at least 3 and p-values below 0.01 across at least 99% of samples.

Third, we used four estimators of epigenetic age (Horvath’s, Hannum’s, PhenoAge and Skin and Blood clocks) with established precision in estimating chronological age, age-related diseases and mortality [16] and constructed with a variety of approaches (blood-based, pan-tissue or phenotype-based).

Finally, our data provide the first evidence of the magnitude and potential consequences of EAA in the Russian population.

6. Conclusions

In this case-control study nested in a prospective population-based cohort, we did not find strong associations between accelerated epigenetic age markers and risk of MI/ACS. There was a modest association between acceleration of epigenetic age and increased risk of MI/ACS confined only to the highest tertile of the PhenoAge clock, which appeared to be partly modulated by smoking and metabolic factors. However, this isolated positive finding may have been a false positive result and needs to be interpreted with caution. If confirmed in larger studies, however, epigenetic age acceleration may prove to be a useful predictor of the risk of acute coronary events in older age, with a potential for practical implications for CVD prevention.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jpm12010110/s1, Figure S1: Boxplots showing age distribution in case and control groups for A—all samples, B—males and C—females. Figure S2: Scatterplots of chronological vs. epigenetic age by Horvath’s, Hannum’s, PhenoAge and Skin and Blood clocks. Black line corresponds to the predicted age equal to the chronological age. Figure S3: Correlation chart for the chronological age and four DNAm age predictions. The panels on the main diagonal show distributions of the CA and DNAm clock results, the panels below the diagonal are scatter plots with a fitted line, the panels above the diagonal show the corresponding Pearson correlation coefficients with significance level below 0.001. Figure S4: Density plots and boxplots of the age acceleration distribution for (A) Horvath’s, (B) Hannum’s, (C) PhenoAge, (D) Skin and Blood epigenetic clocks for sex- and case-control-specific groups. The numbers on the right side of the figure corresponds to t-test p-values. Table S1: Relationship between MI/ACS and epigenetic age acceleration, per 1–year increment of the difference between baseline EA minus CA in men and women (men, n = 171, women, n = 135). Table S2: Distribution of baseline covariates among cases of incident MI/ACS and expanded control sample (cases, n = 129 and controls, n = 265). Table S3: Relationship between MI/ACS and epigenetic age acceleration, per 1–year increment of the difference between baseline EA and CA in the expanded sample (cases, n = 129 and controls, n = 265). Table S4: Relationship between MI/ACS and epigenetic age acceleration in the expanded sample, by tertiles of the difference between baseline EA and CA (cases, n = 129 and controls, n = 265).
Author Contributions: Conceptualization, S.M., M.B., O.C., S.B.; methodology, S.M., O.C., T.T., H.P.; software, O.C., H.P.; validation, O.C., H.P., V.G.; formal analysis, S.M., O.C.; investigation, S.M., V.M., A.R., V.G.; resources, M.B., S.M., V.M.; data curation, S.M., O.C., H.P.; writing—original draft preparation, S.M.; writing—review and editing, O.C., V.M., T.T., A.R., V.G., J.A.H., H.P., S.B., M.B.; visualization, S.M., O.C., A.R.; supervision, S.M., M.B.; project administration, S.M.; funding acquisition, M.B., S.M., T.T. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Russian Scientific Foundation (20–15–00371); the baseline HAPIEE study was funded by the Wellcome Trust (WT064947, WT081081, 106554/Z/14/Z) and the US National Institute of Aging (1R01AG23522).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the ethics committee of IPM—Branch of IC&G SB RAS (Institute of Internal and Preventive Medicine—Branch of Federal State Budgeted Research Institution, ‘Federal Research Center, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences’), Protocol no. 1 from 14 March 2002 and Protocol no. 12 from 8 December 2020. The study did not involve humans or animals.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available in tabulated form on request. The data are not publicly available due to ethical restrictions and project regulations.

Acknowledgments: O. Chervova and S. Beck were supported by grants from the Frances and Augustus Newman Foundation (172074). O. Chervova, S. Beck, M. Bobak and H. Pikhart were supported by EU-H2020 Project ‘CETOOCEN Excellence’ (857560). S. Malayutina, V. Maximov, A. Ryabikov and V. Gafarov were supported by the Russian Academy of Science, State Assignment (AAA–A17–11712850280–2). J.A. Hubacek is supported by project No. 00023001 (ICEM MH CR).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP/248. Available online: https://population.un.org/wpp/Publications/Files/WPP2017_KeyFindings.pdf (accessed on 29 October 2021).
2. WHO/Global Status Report on Noncommunicable Diseases. 2014. Available online: https://www.who.int/publications/i/item/9789241564854 (accessed on 29 October 2021).
3. Jylhävä, J.; Pedersen, N.L.; Hägg, S. Biological Age Predictors. EBioMedicine 2017, 21, 29–36. [CrossRef]
4. Horvath, S.; Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat. Rev. Genet. 2018, 19, 371–384. [CrossRef] [PubMed]
5. Riggs, A.D.; Martienssen, R.F.; Russo, V.E.A. Introduction. Epigenetic Mechanisms of Gene Regulation; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1996.
6. Jones, M.J.; Goodman, S.J.; Kobor, M. DNA methylation and healthy human aging. Aging Cell 2015, 14, 924–932. [CrossRef]
7. Bock, C. Analysing and interpreting DNA methylation data. Nat. Rev. Genet. 2012, 13, 705–719. [CrossRef] [PubMed]
8. Horvath, S.; Zhang, Y.; Langfelder, P.; Kahn, R.S.; Boks, M.P.; Van Eijk, K.; Van den Berg, L.H.; Ophoff, R.A. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012, 13, R97. [CrossRef]
9. Hannum, G.; Guinney, J.; Zhao, L.; Zhang, L.; Hughes, G.; Sadda, S.; Klotzle, B.; Bibikova, M.; Fan, J.-B.; Gao, Y.; et al. Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. Mol. Cell 2012, 49, 359–367. [CrossRef] [PubMed]
10. Weidner, C.I.; Lin, Q.; Koch, C.M.; Eisele, L.; Beier, F.; Ziegler, P.; Bauerschlag, D.O.; Jöckel, K.-H.; Erbel, R.; Mühleisen, T.W.; et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol. 2014, 15, R24. [CrossRef]
11. Bell, C.G.; Lowe, R.; Adams, P.D.; Baccarelli, A.A.; Beck, S.; Bell, J.T.; Christensen, B.C.; Gladyshev, V.N.; Heijmans, B.T.; Horvath, S.; et al. DNA methylation aging clocks: Challenges and recommendations. Genome Biol. 2019, 20, 249. [CrossRef]
12. Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 2013, 14, R115. [CrossRef]
13. Levine, M.E.; Lu, A.T.; Quach, A.; Chen, B.H.; Assimes, T.L.; Bandinelli, S.; Hou, L.; Baccarelli, A.A.; Stewart, J.D.; Li, Y.; et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging 2018, 10, 573–591. [CrossRef]
14. Horvath, S.; Oshima, J.; Martin, G.M.; Lu, A.T.; Quach, A.; Cohen, H.; Felton, S.; Matsuyma, M.; Lowe, D.; Kabacik, S.; et al. Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies. Aging 2018, 10, 1758–1775. [CrossRef]
15. Oblak, L.; van der Zaag, J.; Higgins-Chen, A.T.; Levine, M.E.; Boks, M.P. A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration. Ageing Res. Rev. 2021, 69, 101348. [CrossRef]
16. Lee, Y.; Haftorn, K.L.; Denault, W.R.P.; Nustad, H.E.; Page, C.M.; Lyle, R.; Lee-Odegard, S.; Moen, G.-H.; Prasad, R.B.; Groop, L.C.; et al. Blood-based epigenetic estimators of chronological age in human adults using DNA methylation data from the Illumina MethylationEPIC array. *BMC Genom.* 2020, 21, 747. [CrossRef]

17. Lu, A.T.; Quach, A.; Wilson, J.G.; Reiner, A.P.; Aviv, A.; Raj, K.; Hou, L.; Baccarelli, A.A.; Li, Y.; Stewart, J.D.; et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging* 2019, 11, 303–327. [CrossRef]

18. Shireby, G.L.; Davies, J.P.; Francis, P.T.; Burrage, J.; Walker, E.M.; Neilson, G.W.A.; Dahir, A.; Thomas, A.J.; Love, S.; Smith, R.G.; et al. Recalibrating the epigenetic clock: Implications for assessing biological age in the human cortex. *Brain* 2020, 143, 3763–3775. [CrossRef]

19. Christiansen, L.; Lenart, A.; Tan, Q.; Vaupel, J.; Aviv, A.; McGue, M.; Christensen, K. DNA methylation age is associated with mortality in a longitudinal Danish twin study. *Aging Cell* 2015, 15, 149–154. [CrossRef] [PubMed]

20. Perna, L.; Zhang, Y.; Mons, U.; Holleczek, B.; Saum, K.-U.; Brenner, H. Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort. *Clin. Epigenet.* 2016, 8, 64. [CrossRef] [PubMed]

21. Dugué, P.-A.; Bassett, J.K.; Joo, J.H.E.; Baglietto, L.; Jung, C.-H.; Wong, E.M.; Fioretti, G.; Schmidt, D.; Makalic, E.; Li, S.; et al. Association of DNA Methylation-Based Biological Age With Health Risk Factors and Overall and Cause-Specific Mortality. *Am. J. Epidemiol.* 2018, 187, 529–538. [CrossRef] [PubMed]

22. Marioni, R.E.; Shah, S.; McRae, A.F.; Chen, B.H.; Colicino, E.; Harris, S.E.; Gibson, J.; Henders, A.K.; Redmond, P.; Cox, S.R.; et al. DNA methylation age of blood predicts all-cause mortality in later life. *Genome Biol.* 2015, 16, 25. [CrossRef]

23. Chen, B.H.; Marioni, R.E.; Colicino, E.; Peters, M.J.; Ward-Caviness, C.K.; Tsai, P.C.; Roetker, N.S.; Just, A.C.; Demerath, E.W.; Guan, W.; et al. DNA methylation-based measures of biological age: Meta-analysis predicting time to death. *Aging* 2016, 8, 1844–1865. [CrossRef]

24. Fransquet, P.D.; Wrigglesworth, J.; Woods, R.L.; Ernst, M.E.; Ryan, J. The epigenetic clock as a predictor of disease and mortality risk: A systematic review and meta-analysis. *Clin. Epigenet.* 2019, 11, 62. [CrossRef]

25. Horvath, S.; Gurven, M.; Levine, M.E.; Trumbel, B.C.; Kaplan, H.; Allayee, H.; Ritz, B.R.; Chen, B.; Lu, A.T.; Rickabaugh, T.M.; et al. An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. *Genome Biol.* 2016, 17, 171. [CrossRef] [PubMed]

26. EUROSTAT. Mortality and Life Expectancy Statistics. 2021. Available online: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Mortality_and_life_expectancy_statistics (accessed on 30 October 2021).

27. Global Age Watch Index 2015: Insight report. Available online: https://www.helpage.org/global-agewatch/reports/global-agewatch-index-2015-insight-report-summary-and-methodology/ (accessed on 29 October 2021).

28. Bobak, M.; Malyutina, S.; Horvat, P.; Pajak, A.; Tamosiunas, A.; Kubinova, R.; Simonova, G.; Topor-Madry, R.; Peasey, A.; Pikhart, H.; et al. Alcohol, drinking pattern and all-cause, cardiovascular and alcohol-related mortality in Eastern Europe. *Eur. J. Epidemiol.* 2016, 31, 21–30. [CrossRef]

29. Tillmann, T.; Pikhart, H.; Peasey, A.; Kubinová, R.; Pajak, A.; Tamosiūnas, A.; Malyutina, S.; Steptoe, A.; Kivimäki, M.; Marmot, M.; et al. Psychosocial and socioeconomic determinants of cardiovascular mortality in Eastern Europe: A multicentre prospective cohort study. *PLoS Med.* 2017, 14, e1002459. [CrossRef] [PubMed]

30. Stefer, D.; Brett, D.; Sarkadi-Nagy, E.; Kopczynska, E.; Detchev, S.; Bati, A.; Scrub, M.; Koenker, D.; Aleksov, B.; Douarin, E.; et al. Traditional Eastern European diet and mortality: Prospective evidence from the HAPIEE study. *Eur. J. Nutr.* 2021, 60, 1091–1100. [CrossRef]

31. Ryabikov, A.; Maksimov, V.; Holmes, M.; Bobak, M.; Malyutina, S. The association between epigenetic age and progression of subclinical atherosclerosis in ageing cohort. *Atheroscler* 2020, 315, e132. [CrossRef]

32. Peasey, A.; Bobak, M.; Kubinova, R.; Malyutina, S.; Pajak, A.; Tamosiunas, A.; Pikhart, H.; Nicholson, A.; Marmot, M. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study. *BMC Public Health* 2006, 6, 255–264. [CrossRef]

33. Fortin, J.-P.; Triche, T.J., Jr.; Hansen, K.D. Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics* 2016, 33, 558–560. [CrossRef]

34. Tian, Y.; Morris, T.J.; Webster, A.; Yang, Z.; Beck, S.; Feber, A.; Teschendorff, A. ChAMP: Updated methylation analysis pipeline for Illumina BeadChips. *Bioinformatics* 2017, 33, 3982–3984. [CrossRef]

35. Xu, Z.; Langie, S.A.S.; De Boever, P.; Taylor, J.A.; Niu, L.; De Boever, P. RELIC: A novel dye-bias correction method for Illumina Methylation BeadChip. *BMC Genom.* 2017, 18, 4. [CrossRef]

36. Chervova, O.; Conde, L.; Ver europe-Assunção, J.A.; Moghul, I.; Webster, A.P.; Berner, A.; Cadieux, E.L.; Tian, Y.; Voloshin, V.; Jesus, T.F.; et al. The Personal Genome Project-UK, an open access resource of human multi-omics data. *Sci. Data* 2019, 6, 257. [CrossRef] [PubMed]

37. Fix, E.; Hodges, J.L., Jr. Discriminatory Analysis. Nonparametric Discrimination: Consistency Properties. *Int. Stat. Rev.* 1989, 57, 238–247. [CrossRef]

38. Altman, N.S. An Introduction to Kernel and Nearest-Neighbor Nonparametric Regression. *Am. Stat.* 1992, 46, 175. [CrossRef]

39. Ryabikov, A.; Maksimov, V.; Holmes, M.; Bobak, M.; Malyutina, S. The association between epigenetic age and progression of subclinical atherosclerosis in ageing cohort. *Atheroscler* 2020, 315, e132. [CrossRef]

40. Peasey, A.; Bobak, M.; Kubinova, R.; Malyutina, S.; Pajak, A.; Tamosiunas, A.; Pikhart, H.; Nicholson, A.; Marmot, M. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study. *BMC Public Health* 2006, 6, 255–264. [CrossRef]

41. Fortin, J.-P.; Triche, T.J., Jr.; Hansen, K.D. Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics* 2016, 33, 558–560. [CrossRef]

42. Tian, Y.; Morris, T.J.; Webster, A.; Yang, Z.; Beck, S.; Feber, A.; Teschendorff, A. ChAMP: Updated methylation analysis pipeline for Illumina BeadChips. *Bioinformatics* 2017, 33, 3982–3984. [CrossRef]

43. Xu, Z.; Langie, S.A.S.; De Boever, P.; Taylor, J.A.; Niu, L.; De Boever, P. RELIC: A novel dye-bias correction method for Illumina Methylation BeadChip. *BMC Genom.* 2017, 18, 4. [CrossRef]

44. Chervova, O.; Conde, L.; Ver europe-Assunção, J.A.; Moghul, I.; Webster, A.P.; Berner, A.; Cadieux, E.L.; Tian, Y.; Voloshin, V.; Jesus, T.F.; et al. The Personal Genome Project-UK, an open access resource of human multi-omics data. *Sci. Data* 2019, 6, 257. [CrossRef] [PubMed]

45. Fix, E.; Hodges, J.L., Jr. Discriminatory Analysis. Nonparametric Discrimination: Consistency Properties. *Int. Stat. Rev.* 1989, 57, 238–247. [CrossRef]

46. Altman, N.S. An Introduction to Kernel and Nearest-Neighbor Nonparametric Regression. *Am. Stat.* 1992, 46, 175. [CrossRef]

47. Ryabikov, A.; Maksimov, V.; Holmes, M.; Bobak, M.; Malyutina, S. The association between epigenetic age and progression of subclinical atherosclerosis in ageing cohort. *Atheroscler* 2020, 315, e132. [CrossRef]
40. Marioni, R.; Shah, S.; McRae, A.; Ritchie, S.J.; Terrera, G.M.; Harris, S.E.; Gibson, J.; Redmond, P.; Cox, S.R.; Pattie, A.; et al. The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. *Int. J. Epidemiol.* 2015, 44, 1388–1396. [CrossRef] [PubMed]

41. Levine, M.E.; Lu, A.T.; Bennett, D.A.; Horvath, S. Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer’s disease related cognitive functioning. *Aging* 2015, 7, 1198–1211. [CrossRef]

42. Levine, M.E.; Lu, A.T.; Chen, B.H.; Hernandez, D.G.; Singleton, A.B.; Ferrucci, L.; Bandinelli, S.; Salfati, E.; Manson, J.E.; Quach, A.; et al. Menopause accelerates biological aging. *Proc. Natl. Acad. Sci. USA* 2016, 113, 9327–9332. [CrossRef]

43. Wang, C.; Ni, W.; Yao, Y.; Just, A.; Heiss, J.; Wei, Y.; Gao, X.; Coull, B.A.; Kosheleva, A.; Baccarelli, A.A.; et al. DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4. *EBioMedicine* 2021, 63, 103151. [CrossRef] [PubMed]

44. Roetker, N.S.; Pankow, J.; Bressler, J.; Morrison, A.C.; Boerwinkle, E. Prospective Study of Epigenetic Age Acceleration and Incidence of Cardiovascular Disease Outcomes in the ARIC Study (Atherosclerosis Risk in Communities). *Circ. Genom. Precis. Med.* 2018, 11, e001937. [CrossRef] [PubMed]

45. Horvath, S.; Erhart, W.; Brosch, M.; Ammerpohl, O.; von Schöning, W.; Ahrens, M.; Heits, N.; Bell, J.; Tsai, P.-C.; Spector, T.D.; et al. Obesity accelerates epigenetic aging of human liver. *Proc. Natl. Acad. Sci. USA* 2014, 111, 15538–15543. [CrossRef]

46. Pagadakis, C.; Musolino, E.; Gornati, R.; Bernardini, G.; Papait, R. Epigenetics of aging and disease: A brief overview. *Aging Clin. Exp. Res.* 2021, 33, 737–745. [CrossRef] [PubMed]

47. Fernández-Sanlés, A.; Baixeras, S.S.; Subirana, I.; Degano, I.R.; Elosua, R. Association between DNA methylation and coronary heart disease or other atherosclerotic events: A systematic review. *Atherosclerosis* 2017, 263, 325–333. [CrossRef] [PubMed]

48. Fernández-Sanlés, A.; Sayols-Baixeras, S.; Curcio, S.; Subirana, I.; Marrugat, J.; Elosua, R. DNA Methylation and Age-Independent Cardiovascular Risk, an Epigenome-Wide Approach. *Arter. Thromb. Vasc. Biol.* 2018, 38, 645–652. [CrossRef]

49. Gonzalez-Jaramillo, V.; Portilla-Fernandez, E.; Glisic, M.; Voortman, T.; Bramer, W.; Chowdhury, R.; Roks, A.J.; Danser, A.H.J.; Muka, T.; Nano, J.; et al. The role of DNA methylation and histone modifications in blood pressure: A systematic review. *J. Hum. Hypertens.* 2019, 33, 703–715. [CrossRef]

50. Hartman, R.J.G.; Huisman, S.; Ruijter, H.M.D. Sex differences in cardiovascular epigenetics-a systematic review. *Biol. Sex Differ.* 2018, 9, 19. [CrossRef]

51. Xia, Y.; Brewer, A.; Bell, J.T. DNA methylation signatures of incident coronary heart disease: Findings from epigenome-wide association studies. *Clin. Epigenet.* 2021, 13, 186. [CrossRef]